|Last Price||Today's Change||52-Week Range||Trading Volume|
|61.39||-0.03 (-0.05%)||47.36 - 68.75||1.3 million (Below Avg)|
Market data as of 12:20PM 05/22/15. Quotes are delayed by at least 15 min.
Teva Presents Further Data from Phase IIb with TEV-48125 in Chronic Migraine at the International Headache Society Congress (IHC): Efficacy and Safety Results at All Doses and Endpoints Present Robust Case for Progression to Phase III
05/14/2015 8:30 AM ET